Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease - Wikidata - wikimedia - TriplyDB

Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease

Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease

http://www.wikidata.org/entity/Q28188901

about

The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus Development of paroxysmal nocturnal haemoglobinuria in systemic lupus erythematosus: an unusual cause of portal vein thrombosis.Metabolic alterations and increased liver mTOR expression precede the development of autoimmune disease in a murine model of lupus erythematosus.The role of aspirin in women's health Cardiovascular involvement in connective tissue disease: the role of interstitial lung disease Risk factors in cardiovascular disease in systemic lupus erythematosus.Short- and Long-term Outcomes in Patients with Connective Tissue Diseases Undergoing Percutaneous Coronary Intervention.New developments in lupus-associated antiphospholipid syndrome.Proximal aortic stiffness is increased in systemic lupus erythematosus activity in children and adolescents.Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies.Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors.Current management of antiphospholipid syndrome-related thrombosis.Pathogenesis and treatment of atherosclerosis in lupus.Lactobacillus paracasei GMNL-32 exerts a therapeutic effect on cardiac abnormalities in NZB/W F1 mice.Characteristics and risk factors for hyperglycemia in Chinese female patients with systemic lupus erythematosus.Current causes of death in systemic lupus erythematosus in Europe, 2000--2004: relation to disease activity and damage accrual.Relationship between Neutrophil-to-Lymphocyte Ratio and Pulse Wave Velocity in Young Patients with Systemic Lupus Erythematosus.

P2860

Q28072610-FD99B7F4-0C44-4832-9632-0878646F90A5 Q33384872-B02E869D-B6A9-4CF0-8BB0-4158B6D182F9 Q34506731-D5347889-03F9-4393-B8E6-9198371AA5CF Q35119642-8395EBF9-3273-4AD1-82EF-C57430324EBE Q35182436-D7474111-04AD-4566-A7FD-2F3DB298321A Q36644837-7AAFEDFD-D60D-4BE4-A464-3C8965DFE25B Q36760972-44226A46-45F6-46C3-A806-B7D4447446DF Q37168035-F41D785F-DDC7-42D2-98B8-98B0FED0B147 Q37221927-FA90593E-EB77-4CFA-893F-3632F3DD0CF1 Q37255201-C5CB0E66-7D59-4CC8-AEE2-FA12B7DC0306 Q37425906-780F82ED-E8CA-43CE-BB4A-342AA18EB2F9 Q37642830-B4DAA56D-28E3-4F65-8144-923B644CBACC Q38230699-29C5B946-6FDB-4341-8856-0B45FA299FEA Q42362111-783E3639-DFAB-4733-8C42-878E7A4ECF00 Q42943405-0DD0C6BF-33F0-43E2-8D2E-EC591B4A1E8A Q44699349-50D8A001-CB7B-4DF2-AF42-1EA18C7B5D9D Q47260542-FC8E246B-6021-4CD7-8B4D-ECDB6AB49959

P2860

Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease

http://www.wikidata.org/entity/Q28188901

description

2005 nî lūn-bûn

@nan

2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease

@ast

Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease

@en

Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease

@nl

type

label

Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease

@ast

Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease

@en

Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease

@nl

prefLabel

Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease

@ast

Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease

@en

Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease

@nl

P1433

Q28188901-41C2CF2E-6391-462D-B1FD-C98AE6B5017E

P1476

Q28188901-A10BD4D9-CFF6-417C-ACD1-AFFBD8C146C9

P2093

Q28188901-71431290-BB82-4F64-B0BB-8E4A3782DF00

Q28188901-B0759501-6056-457F-8609-B12E7DEF809C

P2860

Q28188901-027FBD96-0FDC-4046-B855-93A2080E4344

Q28188901-0E749A7E-49E5-4241-BC96-1D3FA9C167AD

Q28188901-15BBDF2E-437B-49D6-AA03-D83BDC570646

Q28188901-17889041-63B4-4909-8D39-C62FE8B52F58

Q28188901-28535B4A-7197-46C9-B8E1-389263F8DB2B

Q28188901-32967B6F-57DE-4904-8567-E0DC9614EE82

Q28188901-3879489F-06C6-4185-987B-4138946A47B5

Q28188901-52AAD84D-3046-42EA-982B-35147962E0C5

Q28188901-621179EA-C2CE-4105-8FFA-2EC487B727BF

Q28188901-72A1D838-67CB-4BE6-9003-C0F262A3B42C

P2888

Q28188901-DF9D16DE-7677-484B-A3B9-D607843006B0

P304

Q28188901-6BDBAEA4-9898-47A4-AE2B-0531D0DAACF9

P31

Q28188901-F62822E4-E1C8-46E1-A0BF-069CB22B4648

P356

Q28188901-61813AC5-6430-4963-B071-FAA7A33CDA7A

P407

Q28188901-9DE9DEC5-B28C-42AE-AFF2-88F6DC898065

P433

Q28188901-620526D2-4745-4BB1-BA4C-8367EB8B7924

P478

Q28188901-760A4E5F-DEBD-4BE2-8117-30C7922CAC58

P577

Q28188901-8FE31D82-9D6D-44AE-84F2-D14719100D83

P6179

Q28188901-F1001EB8-C5EE-4452-97E7-7222272CD120

P698

Q28188901-9F21A7F2-6C4C-49B9-A212-9DF4C6313013

P921

Q28188901-E46F11D4-772F-45B7-9E70-9246D0782011

Q28188901-E4E4833D-6841-438C-9528-D5970E3D5A7D

P356

P1433

Nature Clinical Practice Cardiovascular Medicine

P1476

Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease

@en

P2093

Ian N Bruce

http://www.w3.org/2001/XMLSchema#string

Sahena Haque

http://www.w3.org/2001/XMLSchema#string

P2860

Inflammation, atherosclerosis, and coronary artery disease

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

Factors associated with coronary artery calcification in young female patients with SLE.

Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus.

Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus.

Prevention of cardiovascular disease in systemic lupus erythematosus--proposed guidelines for risk factor management.

Myocardial perfusion scintigraphy and coronary disease risk factors in systemic lupus erythematosus.

Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus

Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome.

Is atherosclerosis an immunologically mediated disease?

P2888

P304

423-30

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCPCARDIO0270

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1024093859

http://www.w3.org/2001/XMLSchema#string

P698

16119705

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio